Hepatic steatosis: A benign disease or a silent killer

被引:53
作者
El-Zayadi, Abdel-Rahman [1 ,2 ]
机构
[1] Cairo Liver Ctr, Giza 12311, Egypt
[2] Ain Shams Univ, Dept Trop Med, Giza 12311, Egypt
关键词
metabolic steatosis; hepatitis C virus steatosis; insulin resistance; fibrosis progression;
D O I
10.3748/wjg.14.4120
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Steatosis is a common feature of many liver diseases' namely non-alcoholic steatohepatitis (NASH) and hepatitis C virus (HCV) infection, but the pathogenic mechanisms differ. Insulin resistance (IR), a key feature of metabolic syndrome, is crucial for NASH development, associated with many underlying genetically determined or acquired mitochondrial and metabolic defects and culminates to inflammation and progression to fibrosis. This may have potential implications for new drug therapy. In HCV-related disease, steatosis impacts both fibrosis progression and response to treatment. Steatosis in HCV-related disease relates to both viral factors (HCV genotype 3), and host factors (alcohol consumption, overweight, hyperlipidemia, diabetes). Among others, IR is a recognized factor. Hepatic steatosis is reported to be associated with disturbance in the signaling cascade of interferon and downregulation of its receptors. Thus, hepatic steatosis should not be considered a benign feature, but rather a silent killer. (C) 2008 The WJG Press. All rights reserved.
引用
收藏
页码:4120 / 4126
页数:7
相关论文
共 76 条
[1]   The natural history of nonalcoholic fatty liver disease: A population-based cohort study [J].
Adams, LA ;
Lymp, JF ;
St Sauver, J ;
Sanderson, SO ;
Lindor, KD ;
Feldstein, A ;
Angulo, P .
GASTROENTEROLOGY, 2005, 129 (01) :113-121
[2]   Recent concepts in non-alcoholic fatty liver disease [J].
Adams, LA ;
Angulo, P .
DIABETIC MEDICINE, 2005, 22 (09) :1129-1133
[3]   Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity [J].
Adinolfi, LE ;
Gambardella, M ;
Andreana, A ;
Tripodi, MF ;
Utili, R ;
Ruggiero, G .
HEPATOLOGY, 2001, 33 (06) :1358-1364
[4]   Steatosis in chronic hepatitis C: Why does it really matter? [J].
Asselah, T ;
Rubbia-Brandt, L ;
Marcellin, P ;
Negro, F .
GUT, 2006, 55 (01) :123-130
[5]   Hypervariable region 1 quasispecies in hepatitis C virus genotypes 1b and 3 infected patients with normal and abnormal alanine aminotransferase levels [J].
Asselah, T ;
Martinot, M ;
Cazals-Hatem, D ;
Boyer, N ;
Auperin, A ;
Le Breton, V ;
Erlinger, S ;
Degott, C ;
Valla, D ;
Marcellin, P .
JOURNAL OF VIRAL HEPATITIS, 2002, 9 (01) :29-35
[6]   Impaired IRS-1/PI3-kinase signaling in patients with HCV: A mechanism for increased prevalence of type 2 diabetes [J].
Aytug, S ;
Reich, D ;
Sapiro, LE ;
Bernstein, D ;
Begum, N .
HEPATOLOGY, 2003, 38 (06) :1384-1392
[7]   The adipocyte-secreted protein Acrp30 enhances hepatic insulin action [J].
Berg, AH ;
Combs, TP ;
Du, XL ;
Brownlee, M ;
Scherer, PE .
NATURE MEDICINE, 2001, 7 (08) :947-953
[8]   The 1st World Congress on the Insulin Resistance Syndrome [J].
Bloomgarden, ZT .
DIABETES CARE, 2004, 27 (02) :602-609
[9]   High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C [J].
Bressler, BL ;
Guindi, M ;
Tomlinson, G ;
Heathcote, J .
HEPATOLOGY, 2003, 38 (03) :639-644
[10]   Molecular mediators of hepatic steatosis and liver injury [J].
Browning, JD ;
Horton, JD .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (02) :147-152